Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - H.C. Wainwright raised its price target on ANI Pharmaceuticals (NASDAQ:ANIP) to $93.00 from $84.00 on Monday, while maintaining a Buy rating on the stock. The company, currently valued at $1.63 billion, has seen its stock surge nearly 25% in the past week alone, according to InvestingPro data.
The price target increase follows ANI Pharmaceuticals’ strong second-quarter 2025 results, which featured significant revenue growth. Cortrophin Gel revenue reached $81.6 million in Q2, representing 66% year-over-year growth compared to Q2 2024 and a 54% sequential increase from Q1 2025. The company’s overall revenue growth stands at an impressive 38.7% over the last twelve months, with five analysts recently revising their earnings estimates upward, as reported by InvestingPro.
Based on these results, ANI Pharmaceuticals has raised its 2025 guidance for Cortrophin Gel to between $322 million and $329 million, up from the previous forecast of $265 million to $274 million.
H.C. Wainwright noted that ANI Pharmaceuticals expects continued growth in the overall ACTH market. The company reported a strong pipeline of new patient starts and new prescribers adopting ACTH treatments.
The pre-filled syringe format of Cortrophin is gaining significant traction, with approximately 70% of new case enrollments in July written for this delivery method, according to company statements cited by H.C. Wainwright.
In other recent news, ANI Pharmaceuticals reported strong financial results for the second quarter of 2025. The company achieved an adjusted earnings per share (EPS) of $1.80, surpassing the FactSet consensus estimate of $1.41. Revenue also exceeded expectations, reaching $211.4 million compared to the forecast of $187.34 million. Following these results, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS. In response to the strong performance, H.C. Wainwright raised its price target for ANI Pharmaceuticals to $93 from $84, maintaining a Buy rating. These developments reflect a positive outlook from analysts and a strong financial standing for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.